(293) Advancing Idiopathic Pulmonary Fibrosis treatment with PROTAC Nanomedicine
Introduction: Idiopathic Pulmonary Fibrosis is a chronic, progressive, and ultimately fatal fibrotic lung disease with a median survival time of 3–4 years after diagnosis, becoming a global concern as its prevalence appears associated with aging. ARV-825 is a PROTAC (Proteolysis-Targeting Chimeras) that offers a novel therapeutic approach for lung fibrosis by regulating pro-fibrotic gene expression in fibroblasts, inhibiting the fibroblast-to-myofibroblast transition and reducing collagen type I production. We developed a PROTAC nanomedicine for intracellular delivery targeting lung fibrosis therapy.
Learning Objectives:
Explore the therapeutic potential of PROTACs for selectively degrading fibrosis-associated proteins.
Delivery system enhanced the therapeutic efficicacy PROTAC in lung fibrosis treatment.
,Xueying Liu – Senior Research Scientist, Innovation Center of Nanomedicine, Kawasaki, Japan; Sabina Quader – Deputy Principal Research Scientist, Innovation center of Nanomedicine, Kawasaki, Japan; Hiroaki Kinoh – Deputy Laboratory Head／Principal Research Scientist, Innovation Center of Nanomedicine, Kawasaki, Japan; Kazunori Kataoka – Deputy Director/Center Director/Lab. Head/Principal Research Scientist, Innovation Center of Nanomedicine
